Cancer vaccination strategies traditionally focus on immune system priming while leaving tumor metabolism untouched—a limitation that may explain why many promising immunotherapies fall short of clinical expectations. This dual-pathway approach could reshape how we design next-generation cancer treatments by simultaneously attacking tumors from two fronts. The investigation centers on engineered dendrimer nanogels measuring 45.7 nanometers that deliver gp100 mRNA to dendritic cells while simultaneously disrupting glucose metabolism in melanoma cells. These pH-responsive carriers incorporate mannose targeting ligands for dendritic cell specificity and crosslinked polyethylene glycol architecture that enables controlled drug release. Testing in subcutaneous mouse melanoma models revealed the platform reduced tumor growth through coordinated immune activation and glycolytic suppression, with enhanced efficacy when combined with PD-L1 checkpoint inhibition. This represents a notable departure from conventional mRNA vaccine design, which typically targets immune cells exclusively while ignoring the metabolic vulnerabilities that cancer cells depend on for rapid proliferation. The dual-mechanism approach addresses a fundamental challenge in cancer immunotherapy: many tumors develop resistance by maintaining robust energy production even when under immune pressure. By constraining glucose utilization—cancer's preferred fuel source—while simultaneously priming cytotoxic T-cell responses, this strategy may overcome metabolic escape mechanisms that limit single-modality treatments. The nanogel architecture also solved delivery challenges that have hindered mRNA therapeutics, achieving stable encapsulation and targeted release. However, the study's reliance on a single melanoma model and subcutaneous injection route leaves questions about broader applicability across cancer types and administration methods that would be clinically relevant.